Skip to content

Biz News Today

Business News – Direct Source News

  • Home
  • Business News Videos
    • International/National News Videos
  • Directory
  • Links PRs
  • REITS
  • About
  • Contact
    • Sitemap

Bristol Myers Squibb Receives Approval for Abecma (idecabtagene vicleucel), the First CAR T Therapy Approved for the Treatment of Multiple Myeloma in Japan

  • Home
  • 2022
  • January
  • 20
  • Bristol Myers Squibb Receives Approval for Abecma (idecabtagene vicleucel), the First CAR T Therapy Approved for the Treatment of Multiple Myeloma in Japan

Original Source

On January 20, 2022

Post navigation

Previous PostSesame Workshop Launches New Resources to Help Children and Families Build a Lifelong Foundation of Resilience
Next PostMarriott International Provides an Update on Development Progress in 2021 and Overview of Key Trends Currently Shaping Hospitality Development

Related Post

May 23, 2022
  • Business News

Taiwan’s Tech Titans Adopt World’s First NVIDIA Grace CPU-Powered System Designs

May 23, 2022
  • Business News

GE Healthcare update on iodinated contrast media

May 23, 2022
  • Business News

Tyson Foods Announces Quarterly Dividend

Copyright © All right reserved
Newslist Created By Rise Themes

Notice: ob_end_flush(): failed to send buffer of zlib output compression (0) in /home/biznews/public_html/wp-includes/functions.php on line 5219